Characteristic | Total (n=20) |
Demographic | |
Age in years, n (%) | |
30–39 | 3 (15) |
40–49 | 1 (5) |
50–59 | 5 (25) |
60–69 | 6 (30) |
70–79 | 4 (20) |
80+ | 1 (5) |
Mean age in years (SD) | 60 (15) |
Female, n (%) | 10 (50) |
Location, n (%) | |
Klinik Favoriten | 19 (95) |
Vienna General Hospital | 1 (5) |
Preferred interview in English, n (%) | 1 (5) |
Socioeconomic | |
Type of education, n (%) | |
Secondary level 1 | 4 (20) |
Secondary level 2 | 8 (40) |
Postsecondary college/short tertiary | 2 (10) |
University | 4 (20) |
Preferred not to say | 2 (10) |
Marital status, n (%) | |
Married/partnered | 15 (75) |
Single | 1 (5) |
Divorced/separated | 3 (15) |
Widowed | 1 (5) |
Number of children, n (%) | |
0 | 2 (10) |
1 | 2 (10) |
2 | 10 (50) |
3+ | 6 (30) |
People in household, n (%) | |
1 | 4 (20) |
2 | 9 (45) |
3–4 | 5 (25) |
5+ | 2 (10) |
Clinical | |
Symptoms on admission, n (%) | |
Cough | 11 (55) |
Sore throat | 5 (25) |
Fever | 11 (55) |
Chills | 6 (30) |
Shortness of breath/difficulty breathing | 9 (45) |
Pain/pressure in the chest | 2 (10) |
Fatigue | 11 (55) |
Nausea, loss of appetite, stomach-ache | 7 (35) |
Diarrhoea | 4 (20) |
Myalgia | 4 (20) |
Dysgeusia | 6 (30) |
Anosmia | 5 (25) |
Pre-existing conditions, n (%) | |
Diabetes | 3 (15) |
Hypertension | 12 (60) |
Cardiovascular disease | 7 (35) |
Chronic lung disease | 5 (25) |
Obesity (BMI>30) | 8 (40) |
Other | 10 (55) |
Treatment for COVID-19, n (%) | |
Camostat (SOC) | 12 (60) |
Hydroxychloroquine/chloroquine | 1 (5) |
Lopinavir/ritonavir | 6 (30) |
Asunercept | 4 (20) |
Remdesivir | 6 (30) |
Glucocorticoids | 14 (70) |
No antiviral treatment | 1 (5) |
Oxygen | |
Oxygen, n (%) | 12 (60) |
Non-invasive ventilation or high-flow devices, n (%) | 7 (35) |
No oxygen, n (%) | 1 (5) |
BMI, body mass index; SOC, Standard of care.